Rockwell Medical (RMTI) Total Non-Current Liabilities (2010 - 2025)
Rockwell Medical (RMTI) posted Total Non-Current Liabilities of $20.2 million for Q4 2025, down 1.48% on a QoQ basis from $20.5 million in Q3 2025, and down 21.3% year-over-year from $25.6 million in Q4 2024.
Rockwell Medical (RMTI) Total Non-Current Liabilities (2010 - 2025) Analysis & Trends
Rockwell Medical's Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $20.2 million for Q4 2025.
- Quarterly Total Non-Current Liabilities fell 21.3% year-over-year to $20.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.2 million (down 21.3% YoY) and the FY2025 annual result came in at $20.2 million, down 21.3% from the prior year.
- Total Non-Current Liabilities was $20.2 million for Q4 2025 at Rockwell Medical, down from $20.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $46.0 million in Q4 2021 and bottomed at $20.2 million in Q4 2025.
- A 5-year average of $30.1 million and a median of $28.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities plunged 33.89% — and 2024, when it climbed 7.7%.
- Rockwell Medical's Total Non-Current Liabilities stood at $46.0 million in 2021, then declined by 29.32% to $32.5 million in 2022, then slipped by 5.11% to $30.9 million in 2023, then decreased by 16.99% to $25.6 million in 2024, then slipped by 21.3% to $20.2 million in 2025.
- Business Quant data shows RMTI's Total Non-Current Liabilities at $20.2 million in Q4 2025, $20.5 million in Q3 2025, and $22.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Rockwell Medical | 25.77 Mn | 1.88 Mn | 2.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.16 Mn |
| Sep 30, 2025 | 20.47 Mn |
| Jun 30, 2025 | 22.22 Mn |
| Mar 31, 2025 | 21.94 Mn |
| Dec 31, 2024 | 25.62 Mn |
| Sep 30, 2024 | 27.94 Mn |
| Jun 30, 2024 | 29.52 Mn |
| Mar 31, 2024 | 30.07 Mn |
| Dec 31, 2023 | 30.87 Mn |
| Sep 30, 2023 | 28.59 Mn |
| Jun 30, 2023 | 28.50 Mn |
| Mar 31, 2023 | 27.92 Mn |
| Dec 31, 2022 | 32.53 Mn |
| Sep 30, 2022 | 38.04 Mn |
| Jun 30, 2022 | 38.96 Mn |
| Mar 31, 2022 | 42.23 Mn |
| Dec 31, 2021 | 46.03 Mn |
| Dec 31, 2020 | 43.58 Mn |
| Sep 30, 2014 | 19.65 Mn |
| Jun 30, 2014 | 21.66 Mn |